News

RedHill Biopharma Acquires Technology from University of Minnesota as Part of Ongoing RHB-104 Phase III Crohn’s Program

RedHill Biopharma Acquires Technology from University of Minnesota as Part of Ongoing RHB-104 Phase III Crohn’s Program   RedHill Biopharma Acquires Technology from University of Minnesota as Part of Ongoing RHB-104 Phase III Crohn’s Program – Hebrew

Read More...

RedHill Biopharma Announces First Patients Enrolled in the Phase III Study of RHB-102 (BEKINDA™) for Gastroenteritis and Gastritis

RedHill Biopharma Announces First Patients Enrolled in the Phase III Study of RHB-102 (BEKINDA™) for Gastroenteritis and Gastritis   RedHill Biopharma Announces First Patients Enrolled in the Phase III Study of RHB-102 (BEKINDA™) for Gastroenteritis and Gastritis – Hebrew

Read More...

RedHill Biopharma Submits BEKINDA™ (RHB-102) European Marketing Authorization Application for Oncology Support

RedHill Biopharma Submits BEKINDA™ (RHB-102) European Marketing Authorization Application for Oncology Support   RedHill Biopharma Submits BEKINDA (RHB-102) European Marketing Authorization Application for Oncology Support – Hebrew

Read More...

RedHill Biopharma and IntelGenx Announce Acceptance for Review of European Marketing Application for RIZAPORT for Migraines

RedHill Biopharma and IntelGenx Announce Acceptance for Review of European Marketing Application for RIZAPORT for Migraines   RedHill Biopharma and IntelGenx Announce Acceptance for Review of European Marketing Application for RIZAPORT for Migraines − Hebrew

Read More...

FDA Grants QIDP Fast-Track Designation to RedHill Biopharma’s Phase III H. pylori Drug RHB-105

FDA Grants QIDP Fast-Track Designation to RedHill Biopharma’s Phase III H. pylori Drug RHB-105   FDA Grants QIDP Fast-Track Designation to RedHill Biopharma’s Phase III H. pylori Drug RHB-105 – Hebrew

Read More...

RedHill Biopharma Reports Results for the Third Quarter of 2014

RedHill Biopharma Reports Results for the Third Quarter of 2014   RedHill Biopharma Reports Results for the Third Quarter of 2014 – Hebrew

Read More...

RedHill Biopharma to Host Third Quarter 2014 Financial Results Conference Call on November 10, 2014

RedHill Biopharma to Host Third Quarter 2014 Financial Results Conference Call on November 10, 2014

Read More...

RedHill Biopharma to Present at the 20th Annual BIO-Europe International Partnering Conference

RedHill Biopharma to Present at the 20th Annual BIO-Europe International Partnering Conference

Read More...

RedHill Biopharma and IntelGenx Submit European Marketing Authorization Application for Migraine Drug RIZAPORT (formerly RHB-103)

RedHill Biopharma and IntelGenx Submit European Marketing Authorization Application for Migraine Drug RIZAPORT (formerly RHB-103)   RedHill Biopharma and IntelGenx Submit European Marketing Authorization Application for Migraine drug RIZAPORT (formerly RHB-103) – Hebrew

Read More...

RedHill Biopharma to Present at the 14th Annual Biotech In Europe Forum for Global Partnering & Investment

RedHill Biopharma to Present at the 14th Annual Biotech In Europe Forum for Global Partnering & Investment

Read More...

News